Wedbush raised the price target for the Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) stock from “an Outperform” to “a Neutral”. The rating was released on October 31, 2022, according to finviz. We previously noted in another research note published on October 31, 2022 by JP Morgan that downgraded the stock from a Neutral to an Underweight with a price target of $7 for YMAB stock. The research report from Canaccord Genuity has resumed the stock to Buy, with a price target set at $35. The stock was initiated by BMO Capital Markets, who disclosed in a research note on June 24, 2022, to Outperform and set the price objective to $27. In their research brief published February 03, 2022, Guggenheim analysts resumed the Y-mAbs Therapeutics Inc. stock to Buy with a price target of $22.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) raised 2.39% to close Wednesday’s market session at $4.29, higher as compared to yesterday’s close. The stock price fluctuated between $4.10 and $4.43 throughout the trading session with the volume trading being 477805 shares, which represented a significant variation when compared to the three months average volume of 599.98K shares. The firm’s stock price fluctuated 9.44% within the last five trades and -71.72% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -59.94% in the last 6 months and -74.69% was subtracted to its value over the previous 3 months. YMAB stock is trading at a margin of -9.93%, -59.20% and -65.27% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, YMAB deals in the Healthcare domain. The stock is trading -79.05 percent below its 52-week high and 45.92 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -47.9. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Y-mAbs Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $181.38 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 4.18 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 1.74, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 12.35 percent of Y-mAbs Therapeutics Inc. shares are owned by insiders, and 65.40 percent are held by financial institutions. Rajah Vignesh, the SVP & CMO at Y-mAbs Therapeutics Inc. (YMAB) has bought 1,195 shares of firm on Nov 15 at a price of $4.92 against the total amount of $5884.0. In another inside trade, Kruse Bo, EVP, CFO, Secretary & Treas. of Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) sold 4,000 shares of the firm on Feb 22 for a total worth of $31400.0 at a price of $7.85. An inside trade which took place on Feb 09, of Y-mAbs Therapeutics Inc. Gad Thomas sold 64,276 shares of firm against total price of $0.45 million at the cost of $6.96 per share.